Recent clinical trials in superficial bladder cancer.
The present review addresses literature regarding the management of superficial bladder cancer published since March 2000. There is no definitive winner among urinary markers of bladder cancer, because they lack specificity or are insufficiently tested. Pathologists continue in their efforts to improve prediction of evolution of superficial bladder cancer to recurrent or infiltrative disease. A few studies have confirmed the value of previously described prognostic factors for recurrence and progression, and have added some refinements. Transurethral resection is not as complete as was believed. Fluorescence detection of flat bladder carcinoma has been demonstrated to improve diagnosis and treatment. The necessity to perform a repeat transurethral resection in high-grade superficial bladder cancer became evident. Identification of the working mechanisms of bacille Calmette-Guérin on superficial bladder cancer remains an important objective, and may help to improve treatment schedules and avoid the morbidity associated with bacille Calmette-Guérin administration. Patients who are at high risk may benefit from long-term maintenance bacille Calmette-Guérin therapy. Valrubicin and keyhole limpet haemocyanin appear to be promising agents in the treatment of superficial bladder cancer.
Oosterlinck
W
W
Department of Urology, University Hospital Ghent, Ghent, Belgium. willem.oosterlinck@rug.ac.be
D000970:Antineoplastic Agents / Q000008:administration & dosage; D014408:Biomarkers, Tumor; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D015653:Cystectomy / Q000379:methods; D003558:Cystoscopy; D005260:Female; D006801:Humans; D008297:Male; D009163:Mycobacterium bovis; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor